×
EUTOS Long-Term Survival Score Outperforms Sokal in TKI-Treated CML
https://www.cancertherapyadvisor.com/chronic-myeloid-leukemia/eutos-long-term-survival-score-outperforms-sokal-tki-treated-cml/article/819747/

Dec 6th, 2018 - The EUTOS long-term survival score (ELTS) better discriminates patients for risk stratification than the standard Sokal score, according to findings from an analysis of data from 904 patients treated with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) who had enrolled in 6 multicenter studies.

VTE Clinical Practice Guidelines
https://content.jwplatform.com/players/IN0W1T7P-Y8T7ZZf0.html

Dec 6th, 2018 - Six new Clinical Practice Guidelines on Venous Thromboembolism have just been announced.

Choosing Wisely Champions Initiative
https://content.jwplatform.com/players/jc7zyb6N-Y8T7ZZf0.html

Dec 6th, 2018 - Each year, ASH’s Choosing Wisely Champions Initiative recognizes three practitioners who are working to eliminate costly and potentially harmful overuse of tests and procedures.

Plenary Scientific Session
https://content.jwplatform.com/players/uuJmGHb6-Y8T7ZZf0.html

Dec 6th, 2018 - The plenary scientific session is a highlight of the annual meeting, where attendees hear presentations of the 6 highest caliber scientific abstracts.

Late Breaking Abstracts & Best of ASH
https://content.jwplatform.com/players/PZ7jwRI8-Y8T7ZZf0.html

Dec 6th, 2018 - A preview of the Late Breaking Abstracts and The Best of ASH.

Global Programs & Capacity Building Showcase
https://content.jwplatform.com/players/qo6WKBvL-Y8T7ZZf0.html

Dec 6th, 2018 - The society continues to grow its international influence and help improve hematologic care around the globe.

Look Ahead to 2019
https://content.jwplatform.com/players/yJp2IcQE-Y8T7ZZf0.html

Dec 6th, 2018 - A look ahead to 2019, with ASH President-Elect, Dr. Roy Silverstein

Dynamic Scientific Panels & Presentations
https://content.jwplatform.com/players/PwoNW63L-Y8T7ZZf0.html

Dec 6th, 2018 - A look at some of the dynamic scientific panels and presentations including the new frontier of glycobiology and new insights into neonatal hematology

Highlights from Scientific Spotlight Sessions
https://content.jwplatform.com/players/Pu7DTVEk-Y8T7ZZf0.html

Dec 6th, 2018 - Scientific spotlight sessions at the ASH annual meeting provided an in-depth review of specific scientific topics.

Clinical Practice Guidelines for SCD
https://content.jwplatform.com/players/WKvxizqD-Y8T7ZZf0.html

Dec 6th, 2018 - ASH is developing new clinical practice guidelines on the management of acute and chronic complications of sickle cell disease

Ibrutinib + Rituximab Reportedly Superior to Current Standard of Care in Younger Patients With CLL
https://www.cancertherapyadvisor.com/ash-2018/leukemia-cll-ibrutinib-rituximab-reportedly-superior-younger-patients-risk/article/819194/

Dec 5th, 2018 - The combination of ibrutinib and rituximab provided superior progression-free survival and, after follow-up, superior overall survival, compared with the current standard of care, chemoimmunotherapy (CIT) fludarabine, cyclophosphamide, and rituximab (FCR), in treatment-naive patients younger than 70 years with chronic lymphocytic leukemia (CLL), according to research presented at a late-breakin...

Another Rituximab Biosimilar Passes Lymphoma Test
https://www.medpagetoday.com/meetingcoverage/ashhematology/76747

Dec 5th, 2018 - A rituximab biosimilar demonstrated noninferiority to European (EU)-licensed rituximab (MabThera) in a randomized trial involving patients with low-tumor burden follicular lymphoma

Daratumumab Plus Len/Dex: New Standard of Care in Myeloma?
https://www.medscape.com/viewarticle/906121

Dec 5th, 2018 - In the MAIA study, adding the monoclonal antibody daratumumab (Darzalex, Janssen) to standard therapy significantly extended progression-free survival (PFS) in patients newly diagnosed with multiple myeloma who were ineligible for stem cell transplant.

The Long-Term Outlook for Mogamulizumab in Previously Treated Cutaneous T-Cell Lymphoma
http://www.cancernetwork.com/ash-lymphoma/long-term-outlook-mogamulizumab-previously-treated-cutaneous-t-cell-lymphoma

Dec 5th, 2018 - The results of a follow-up analysis to the phase III MAVORIC study were presented at the ASH 2018 Annual Meeting & Exposition.

Rivaroxaban may reduce VTE risk in cancer patients
https://www.mdedge.com/hematologynews/article/190551/thrombosis/rivaroxaban-may-reduce-vte-risk-cancer-patients

Dec 5th, 2018 - The CASSINI trial evaluates VTE prophylaxis in ambulatory patients receiving systemic therapy.

Daratumumab Combination: New Standard of Care in Transplant-Ineligible Multiple Myeloma
https://www.cancertherapyadvisor.com/multiple-myeloma/multiple-myeloma-daratumumab-combo-new-standard-care-transplant-risk/article/819214/

Dec 5th, 2018 - Adding daratumumab to standard treatment with lenalidomide and dexamethasone (DRd) reduced the risk of progression or death by 44% among patients with transplant-ineligible newly-diagnosed multiple myeloma, according to an interim analysis of data from the randomized, open-label, multicenter phase 3 MAIA clinical trial

Cancer-VTE Trial Falls Short
https://www.medpagetoday.com/meetingcoverage/ashhematology/76719

Dec 4th, 2018 - A closely watched trial of venous thromboembolism (VTE) prevention with an oral anticoagulant in cancer patients fell short of a clear win, but not because the drug didn't work, according to a report here.

Tait D. Shanafelt, MD, on CLL: Results From a Trial of the ECOG-ACRIN Cancer Research Group
http://www.ascopost.com/videos/2018-ash-annual-meeting-exposition/tait-shanafelt-on-cll-results-from-a-trial-of-the-ecog-acrin-cancer-research-group/

Dec 4th, 2018 - Tait D. Shanafelt, MD, of Stanford University, discusses phase III study findings on ibrutinib-based therapy vs standard fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy